Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
Authors' conclusion
Dapagliflozin + SoC was not cost-effective versus canagliflozin + SoC in patients with CKD and T2D over the lifetime horizon. However, adding canagliflozin or dapagliflozin to SoC was less costly and more effective relative to SoC alone for treatment of CKD and T2D.
Study context
- Population
- Patients with chronic kidney disease (CKD) and T2D
- Comparison
- Canagliflozin + standard of care (SoC) or dapagliflozin + SoC vs SoC alone
- Outcome
- Cost-effectiveness: costs (2021 C$) and QALYs
- Follow-up
- Lifetime
Methodological detailsMarkov microsimulation model, healthcare system perspective, lifetime horizon, 2021 Canadian dollars
- Markov microsimulation model
- Healthcare system perspective
- Lifetime horizon
- 2021 Canadian dollars
Main finding
As reported in the abstract
Cost savings and QALYs vs SoC alone
Cost savings
33 460 C$
Canagliflozin + SoC · 1.38 additional quality-adjusted life-years (QALYs)
Cost savings
26 764 C$
Dapagliflozin + SoC · 1.44 additional QALYs
Further findings
Dapagliflozin + SoC vs canagliflozin + SoC · lifetime
- Higher QALY gains but more costly with dapagliflozin + SoC; ICER exceeded willingness-to-pay threshold of C$50 000 per QALY
Dapagliflozin + SoC vs canagliflozin + SoC · 5 or 10 years
- Dapagliflozin + SoC generated cost savings and QALY gains vs canagliflozin + SoC
Original publication
Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab. Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →